Latest News
4basebio announces Phase I cell therapy programme partnership with TriLink
28 September 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) reported on Monday that it is to supply clinical-grade opDNA synthetic DNA for a multinational pharmaceutical company's Phase I cell therapy programme, extending a...
Kodiak Sciences to present topline Phase 3 study results for Zenkuda and KSI-501 in wet AMD
28 September 2026 - Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, said on Friday that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and K...
IASO Bio presents first-in-human data of BCMA-targeted in vivo CAR-T cell therapy IASO206 at 2026 IMS
28 September 2026 - Chinese commercial-stage biopharmaceutical company IASO Biotechnology (IASO Bio) announced on Saturday the presentation of first-in-human (FIH) Phase 1 clinical data for IASO206, its internally developed BCMA-targeted in vivo CAR-...
Leo Cancer Care invests in children's experience of radiotherapy, following world-first treatments
28 September 2026 - Radiotherapy technology company Leo Cancer Care on Sunday announced plans to further invest in the treatment experience for children undergoing radiation therapy.Following the world's first paediatric treatments using an upri...
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
28 September 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday an expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 (Takeda R&D code: TAK-928) in patients with squamous n...